title: [Somatostatin receptor status in non-medullary thyroid carcinoma].
abstract: OBJECTIVE
  Recent in-vitro and in-vivo studies demonstrated a somatostatin receptor expression in some non-medullary thyroid carcinomas. In this study we investigated the somatostatin receptor status for this particular tumor entity in a larger patient group.
  
  
  METHODS
  We compared 131-iodine with 111-In-pentetreotide scans in 24 patients with metastasizing, non-medullary thyroid cancer. The findings were correlated with other imaging modalities. Additionally, we performed receptor autoradiography in one patient, octreotide therapy in another patient and administration of 90-Y- and 111-In-DOTATOC in 2 consecutive patients.
  
  
  RESULTS
  In the 15 patients with papillary or follicular carcinoma, 111-In-pentetreotide was inferior to 131-I in 8/15, equal in 1/15, and superior in 6/15 patients. In 8/9 of the patients with Hürthle cell carcinoma, metastases showed a 111-In-pentetreotide accumulation of various intensity, while 131-iodine scans were negative except for one patient. 111-In-pentetreotide was equal or superior compared to 201-Tl or 99m-Tc-sestamibi, but for the most part inferior in comparison with 18-F-FDG-PET. The findings of 111-In-pentetreotide scintigraphy correlated well with the receptor autoradiography and the accumulation of DOTATOC, but not with the therapeutic effect of "cold" octreotide on the thyroid cancer metastases.
  
  
  CONCLUSIONS
  Several metastases of papillary and follicular carcinoma, and the majority of Hürthle cell cancer metastases can express somatostatin receptors. 111-In-pentetreotide scintigraphy is a promising tool for localization of metastases especially in Hürthle cell cancer or if PET is not available, and may be useful for selection of possible candidates, if therapeutic effective beta-emitting somatostatin analogues will be available for routine application.
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Universitätskliniken Essen, Deutschland.
authors.forename: R
authors.initials: R
authors.lastname: Görges
authors.forename: G
authors.initials: G
authors.lastname: Kahaly
authors.forename: J
authors.initials: J
authors.lastname: Müller-Brand
authors.forename: H
authors.initials: H
authors.lastname: Mäcke
authors.forename: S
authors.initials: S
authors.lastname: Walgenbach
authors.forename: C
authors.initials: C
authors.lastname: Bruns
authors.forename: J
authors.initials: J
authors.lastname: Andreas
authors.forename: K
authors.initials: K
authors.lastname: Brandt-Mainz
authors.forename: A
authors.initials: A
authors.lastname: Bockisch
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D001345:Autoradiography; D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D017481:Receptors, Somatostatin / Q000032:analysis*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D014055:Tomography, Emission-Computed; D015021:Yttrium Radioisotopes